U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT06986174) titled 'A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenstrom Macroglobulinemia' on May 15.
Brief Summary: This study is being done to examine the safety and effectiveness of pacritinib as a possible treatment for participants with Waldenstrom macroglobulinemia (WM).
The name of the study drug involved in this study is:
-Pacritinib (a type of kinase inhibitor)
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Waldenstrom Macroglobulinemia
Lymphoplasmacytic Lymphoma
B-Cell Lymphoproliferative Disorder
Indolent Lymphoma
Intervention:
DRUG: Pacritinib
Kinase inhibitor, ...